WHO certifies more HPV tests to fight cervical cancer

WHO has added a fourth test to its list of prequalified tests for human papillomavirus (HPV). Most HPV infections clear up on their own, but some high-risk types can cause cervical cancer. Testing for HPV infection is an integral part of cervical cancer screening.

“A key pillar of the cervical cancer elimination strategy is for countries to increase their screening uptake with high performance tests. ,” said Dr Bente Mikkelsen, Director of the WHO Non-Communicable Diseases Division. This is an important step towards eradicating cervical cancer. “

The WHO In Vitro Diagnostic (IVD) Prequalification (PQ) Program evaluates a variety of tests, including those used to detect high-risk HPV genotypes in cervical cancer screening. The addition of another product to the PQ list will expand the range of high-performance tests available in each country, especially where governments, UN agencies or partners rely on the WHO scheme to assist with procurement .

The recent addition of the cobas HPV assay from Roche Molecular Systems Inc. brings the total number of tests listed to four, including CareHPV Test from QIAGEN GmBH, Abbott RealTime High Risk HPV from Abbott GmbH and Cepheid AB’s Joined Xpert HPV.

After WHO Director-General Dr Tedros Adhanom Ghebreyesus issued a call to action in 2018, the World Health Assembly passed a historic resolution calling for the first-ever eradication of cancer. Since then, WHO has supported countries through major efforts to eliminate cervical cancer.

The global strategy sets goals for each of the three strategic pillars. If this goal is achieved by 2030, countries will be on the road to eradicating cervical cancer.

  • Ninety percent of girls are fully HPV-vaccinated by age 15.
  • Seventy percent of women were screened using a high performance test by age 35 and screened again by age 45.
  • Ninety percent of women with precancerous cancer were treated and 90% of women with invasive cancer were managed.

Even in countries where the HPV vaccine has been introduced, screening programs to identify and treat cervical precancerous conditions and cervical cancer remain important to reduce cervical cancer incidence and mortality. is.

HPV testing outperforms alternative screening methods such as Pap smears and visual acetic acid testing (VIA) and helps identify more patients in need of treatment. Higher quality also means that patients with a negative HPV test can wait longer between tests, benefiting both patients and healthcare systems. Additionally, some of her HPV tests also allow patients to collect their own samples with a simple cotton swab, allowing women to be tested without having to ask a healthcare provider to perform a vaginal examination. Many of her HPV tests can be integrated into existing testing systems, especially since they can be performed on the same equipment used for COVID-19 PCR tests and HIV tests. Such innovations will further reduce barriers to service and help public health programs reach their 70% screening goal.

Disclaimer: Inclusion in this list does not constitute an endorsement or endorsement by WHO of the suitability of the product for any particular purpose, including with respect to safety and/or efficacy. For a full list of disclaimers and additional information, see Prequalified In Vitro Diagnostics | WHO – Prequalification of Medical Products (IVDs, Medicines, Vaccines and Immunization Devices, Vector Control).

/ Open to the public. This material from the original organization/author may be of the nature of its time and has been edited for clarity, style and length. Mirage.News does not take any organizational positions or positions and all views, positions and conclusions expressed herein are those of the authors only. Read the full article here.

#certifies #HPV #tests #fight #cervical #cancer

Be the first to comment

Leave a Reply

Your email address will not be published.